The Hidden Cost of Blunt Biochemistry: Why the Right Treatment Depends on the Right Signal

When a treatment helps one person and harms another, the real question is not whether it works. It is whether it is listening.

A sleep aid can speed up metabolism in the liver, changing how long it lingers in the body. A glutamate blocking drug can help some autistic youths socially, while making others more agitated or anxious. Those two facts live in different corners of medicine, yet they point to the same uncomfortable truth: biology is not a switch, it is a conversation.

We still talk about many treatments as if they are universal tools. Take a dose, get a result. But the more closely we look, the more that model collapses. The same substance can be calming at one dose and disruptive at another. The same drug can work brilliantly in one subgroup and fail in another. The same symptom can come from different biological routes, which means the same intervention may be either useful or misleading.

That is the deeper tension connecting these findings: medicine often treats averages, while bodies live in mechanisms.

---

The problem with blunt instruments

The appeal of a treatment is obvious. If you are exhausted, sleep feels like a universal good. If a teenager struggles with social reciprocity, any option that improves communication seems worth exploring. But the body does not respond to intention. It responds to pathways, timing, dose, and context.

This is where the first idea becomes important. A compound that affects sleep can also interact with liver enzymes such as CYP1A2, which changes how quickly it is broken down. That means the same bedtime pill may produce very different exposures depending on biology, co medications, and metabolism. What looks like a simple supplement is actually part of a larger network of chemical traffic.

That same principle appears in the autism trial. Memantine, a glutamate modulator, did not behave like a universally effective social treatment. It appeared to help some youths substantially, especially those with high glutamate levels in the pregenual anterior cingulate cortex, while doing little or even worse than placebo in those without that abnormality. The striking result is not just that the drug worked. It is that its benefit depended on whether the brain was already signaling the problem it was designed to address.

This is a profound shift in how we should think about interventions. A treatment should not be judged only by whether it can move an outcome in a trial. It should also be judged by what kind of problem it is built to solve.

The most effective medicine is rarely the strongest medicine. It is the medicine matched to the signal.

---

The body as an information system

A useful mental model here is to think of the body as an information system rather than a machine with one broken part. In a machine, a single replacement part can restore function. In an information system, symptoms are often the visible output of a deeper communication failure.

Sleep is not merely about sedation. It is about circadian timing, receptor sensitivity, clearance rates, and the body’s ability to recognize night as night. Social functioning is not merely about being calmer or less anxious. It is about how the brain filters salience, regulates excitation, and translates perception into interaction. In both cases, the problem is not just the presence of a symptom. It is the state of the system that generates the symptom.

That is why one size fits all treatment often disappoints. If a drug is placed into a system whose underlying signal does not match the drug’s target, it can become noise. It may still produce a measurable change, but not necessarily a meaningful one. Worse, it may push a balanced system out of balance.

The memantine findings make this vividly concrete. Participants with high glutamate appeared to benefit, and nearly all responders showed improvement by week 6. But in participants with medium glutamate levels, the drug did not just lose power. It appeared to perform worse than placebo. That is not a failure of the idea that glutamate matters. It is evidence that glutamate matters in a conditional way.

This is how precision medicine should be understood. Not as a futuristic luxury, but as a basic correction to a long standing error: assuming that similar symptoms imply identical mechanisms.

---

Why biomarkers matter more than we admit

People often imagine biomarkers as technical extras, useful for research but not essential in practice. That view is outdated. Biomarkers are not merely labels. They are decision filters.

Imagine trying to tune a radio in a storm. If you keep turning the dial blindly, you may eventually hear music, or you may amplify static. A biomarker is the signal meter that tells you whether you are near the station. In the autism trial, elevated glutamate in the pregenual anterior cingulate cortex functioned like that signal meter. It helped identify who was biologically closer to the mechanism memantine was designed to influence.

The sleep example offers a parallel lesson. If a compound increases the activity of CYP1A2, its effect may be shaped by whether a person already has rapid metabolism, uses other medications, or has a physiology that clears the compound quickly. In other words, the real question is not just what a treatment contains. It is where it enters the metabolic network and how that network processes it.

This matters because many disappointing treatments are not actually ineffective. They are undifferentiated. They are tested against broad diagnostic categories that hide meaningful biological diversity. A treatment can appear mediocre when averaged across a mixed population, even if it is highly effective for a well defined subgroup.

That is the hidden opportunity in these findings. The future of treatment may depend less on discovering one universally superior intervention and more on learning how to sort people into the right mechanistic lanes before treatment begins.

---

The paradox of targeted treatment: more precision, more caution

Precision sounds reassuring, but it raises a harder question. If a treatment works only for a subgroup, how do we avoid overconfidence and overuse? The answer is to remember that targeted therapy is not the same thing as guaranteed therapy.

The memantine trial is encouraging, but it also contains warning signs. Some participants withdrew because of worsening anxiety, irritability, or agitation during titration. Even when a biological target is real, the route to benefit can be unstable. A mechanism may be relevant and still be sensitive to dose, timing, comorbidities, or developmental stage.

This is the part many people miss when they hear about promising subgroup findings. The lesson is not, “find the marker and the problem disappears.” The lesson is, “the marker tells you where to look, not that the terrain is simple.”

Think of it like using a key on a lock. A good key is necessary, but not sufficient. The door may still stick, the hinge may be damaged, or the lock may be misaligned. Likewise, a person with high glutamate may still need careful titration, monitoring for activation, and attention to other psychiatric symptoms. A biomarker improves the odds of a good match, but it does not eliminate the complexity of the system.

This is also why the liver metabolism point matters so much. A treatment can be theoretically suitable and still become practically unsuitable if metabolism changes exposure too much. The right mechanism does not rescue the wrong dose. The right dose does not rescue the wrong mechanism.

Precision medicine fails when it becomes a slogan. It succeeds when it becomes a method for reducing mismatch.

---

A more honest framework: from symptoms to states to signals

If we want a better way to think about treatment, we need a framework that moves beyond diagnosis alone. One useful model is Symptoms, States, Signals.

1. Symptoms are what we observe: insomnia, social difficulty, irritability, agitation.
2. States are the system conditions producing those symptoms: hyperarousal, neurotransmitter imbalance, rapid metabolism, developmental vulnerability.
3. Signals are the measurable clues that tell us which state is present: enzyme activity, glutamate levels, response patterns over time.

Traditional medicine often begins and ends with symptoms. But symptoms are the least specific layer. Two people can both sleep poorly for completely different reasons. Two autistic youths can both struggle socially while one has elevated glutamatergic activity and another does not. If we skip the state and signal levels, we are guessing with confidence.

This does not mean every treatment requires an expensive scan or elaborate lab panel. It means we should become more disciplined about asking: what kind of problem is this treatment designed to solve? If the answer is a metabolic mismatch, then enzyme interactions matter. If the answer is a neurotransmitter imbalance in a subgroup, then biomarkers matter. If the answer is neither, then the intervention should not be marketed as though it is.

The practical payoff of this framework is humility. It encourages us to expect variation instead of treating it as failure. It also explains why some therapies look underwhelming until they are paired with the right measurement strategy. In many cases, the issue is not that biology is unknowable. It is that we have been asking the wrong level of question.

---

What this means for patients, clinicians, and families

For patients and families, the key shift is this: do not ask only, “Does it work?” Ask, “For whom, under what conditions, and by what mechanism?” That question is more demanding, but it is also more protective.

For clinicians, the challenge is to resist treating every option as equally applicable at the start. A treatment that changes metabolism or neurotransmission can be useful, but only if the surrounding context supports it. That means paying attention to co medications, developmental stage, symptom profile, and emerging biomarkers when available.

For researchers, the task is even clearer. Broad diagnostic labels are useful for organizing care, but they are too crude for mechanism driven treatment development. Trials should increasingly ask whether the intervention has an identifiable biological niche. If it does, then the next step is not bigger averages. It is sharper stratification.

There is a deeper cultural lesson too. We often interpret side effects as bad luck and response as good luck. But both are often data. Anxiety during titration may reveal that the target is being overshot or that the person’s system is sensitive to activation. Strong response in a high glutamate subgroup may reveal that the mechanism was correctly identified. In both cases, the body is providing feedback. The art of medicine is learning to read it.

---

Key Takeaways

• Do not confuse symptom relief with mechanism matching. A treatment can improve a symptom without addressing the right underlying state.
• Look for biological signals before assuming broad benefit. Biomarkers such as glutamate levels or metabolic enzyme activity can identify who is more likely to respond.
• Treat side effects as information, not just inconvenience. Agitation, anxiety, or insomnia during titration may indicate a mismatch in dose, target, or patient subgroup.
• Remember that averages can hide strong subgroup effects. A drug that looks modest overall may be highly effective for a biologically distinct subset.
• Ask three questions before trusting a treatment: for whom, by what mechanism, and at what cost?

---

The real lesson: medicine works best when it stops pretending that all bodies are average

The deepest insight here is not simply that some drugs are metabolized differently, or that some brain mechanisms matter more in certain people. It is that variation is not noise around the truth. Variation is often the truth.

A sleep compound that alters liver metabolism reminds us that the body is always processing, adapting, and recalibrating. A glutamate modulator that helps only those with elevated glutamate reminds us that symptoms can be biologically diverse even when they look similar on the surface. Together, they challenge a comforting but outdated assumption: that one treatment can speak equally well to every body.

The future of better care will not come from more forceful interventions. It will come from more accurate listening. That means listening to metabolism, listening to brain chemistry, listening to side effects, and listening to the differences hidden inside broad diagnoses.

In the end, the real advance is not that medicine becomes more complicated. It is that medicine becomes more honest: the right treatment is not the one with the biggest effect, but the one that recognizes the signal already present in the person in front of you.